Method for treating the cases of oncological diseases

FIELD: medicine.

SUBSTANCE: method involves administering Jungar monkshood preparation into patient organism in daily increasing doses. Jungar monkshood extraction is used as the preparation. It is introduced in initial dose of 120 ng when taking into consideration total alkaloids and uniformly increasing the dose during 20 days until the dose of 2.4 mcg is reached. Then, Jungar monkshood extraction administration is continued at the same dose in combination with TGF-β protein at a dose of 15 mcg. Next, Jungar monkshood extraction sole is introduced in uniformly reducing the dose to 120 ng.

EFFECT: reduced risk of tumor recurrence.

 

The invention relates to medicine and can be used to treat cancer.

There is a method of treatment of cancer, including reception of alcohol tinctures of red toadstool, which begin with a dose of 750 mg and increase each subsequent admission to 10-12%, optionally admit 40-60%alcohol tincture of Aconite root Junggar at a dose of 750 mg and increase by 7-10% daily, then after 5-15 minutes take 30-50%alcohol tincture of the herb Hemlock spotted at a dose of 750 mg and increase by 7-10% in each subsequent reception, then dry the root of Euphorbia Pallas dose of 0.04-0.1 and drink his 50 ml of broth from the first harvest including grass mistletoe and grass celandine when the mixing ratio of 1:2, then take 30-50%alcohol tincture of Echinacea in a dose of 5 ml and then increase the dose up to 12 ml, and also take 50 ml of the decoction of the second collection, including the herb yarrow, grass water pepper, herb wormwood white when the mixing ratio 2:1:1, then 50 ml of the third collection, including the bergenia root tolstolistnogo, the herb St. John's wort herb, herb, sage and grass Ivan-tea in the ratio 1:2: 1:1 then take 750 mg 70-96%alcohol tincture of propolis, treatment 1-4 times a day, within a 1.5-6 months 2 times a year (see RF patent №2028808, class A 61 K 35/78, 1995) - the closest analogue.

Analysis of the known method of treatment shows that it is characterized by the use of a significant amount of drugs in strictly defined proportions in a long time. For example, the treatment lasts for one year, which in some cases is unacceptable, because the drugs used for treatment are such that even a slight overdose or long-term use is very dangerous, especially because almost simultaneous application of several of them greatly heightens the effect, which can lead to the defeat is not susceptible organs.

The present invention is to develop an effective method of cancer treatment that uses a minimum of drugs that minimize adverse organs and reduces the time of treatment.

The task is provided by the fact that the method of treating cancer, comprising introducing into the patient of the drug on the basis of Aconite in Dzhungarskiy daily increasing doses, what's new is that this drug is used extract of Aconite Jungar, which is injected from the dose by total alkaloids 120 ng, evenly increasing the dose during the 20 days to reach the value of 2.4 μg dose; during the next 20 days continue administration of the extract of Aconite in Dzhungarskiy sing dose together with activin - protein family of TGF-β at the dose of 15 mcg; followed by the introduction of only one extract of Aconite Junggar with uniform daily dose reduction to 120 ng.

Gradually increase dosage to a maximum, within a certain time maximum doses and gradually reducing them to a minimum allows, gradually increasing the adaptive reserves of the body, to make it resistant to toxic doses of Aconite Jungar, to sustain the body in this mode, accumulating toxic dose and gradually subtracting them without causing a sharp decrease in concentration of the active start.

It should be noted that in medical practice for the treatment of cancer are traditionally used highly toxic components (alkylating, anticancer antibiotics, and others), which are toxic to both malignant and any normal cells. In contrast, the Aconite Jungar in these concentrations does not affect normal cells as stem and differentiated.

In medical practice for a long time, traditionally used for the treatment of cancer infusions and extracts of various plant collections. However, almost in the ex these drugs are highly toxic components, which have a sharply negative impact on the body, which limits their use and reduces the effectiveness of the treatment.

Very widely used in medicinal preparations for treatment of oncological diseases and the preparation of Aconite Jungar. Installed the possible mechanism of action of this drug - repression of gene expression Tue, fos, and jim. However, the application of the actual drug Aconite Junggar may not always provide effective treatment. Therefore, it is used in composition with other components, which reduce its toxic action and the effectiveness of the treatment.

Anticancer effect of the protein family of TGF-β shown in many studies, and confirmed by our own research and practice. However, a broad introduction into medical practice of this protein prevents not only its high price, but the protection of most cancers cells from attack by this factor differentiation enabling rapid proliferation, in the known cases, when proteins are a family of TGF-β not only inhibited tumor growth but stimulated him. One of the necessary stages of this type of proliferation of tumor cells involves the overexpression of genes myc, fos, and jim. We hypothesized that the combined use of the drug on the basis of Aconite Junggar and activin protein family GF-β should produce a strong synergistic effect, which in turn will help to overcome the disadvantages of both drugs used separately - high toxicity of plant extracts and high cost and lack of reliability of protein drugs.

We examined the synergistic antitumor effects of both drugs on mice with implanted human tumors. How to reduce tumor growth and prolong the life of mice, we have observed a very strong synergistic effect.

Therefore, it has proved very promising cancer treatment joint use of the drug Aconite Junggar and protein family of TGF-β (activin).

The combination of these drugs when used allows you to reduce the toxic effects of Aconite Junggar on the body, but at the same time exclude the possibility of growth of tumors encountered in the use of protein drugs, which gives the opportunity to increase the effectiveness of the treatment, can reduce the amount of drugs and to reduce the treatment time.

Technology and manufacture of drugs known, they are not subject to patent protection and therefore in the application materials are not disclosed.

When conducting patent research is not detected solution, identical specifications, and traces the tion, the claimed invention meets the criterion of "novelty".

We believe that the essence of the claimed invention should not be explicitly known solutions, and therefore, the claimed method meets the criterion of "inventive step".

We believe that the information set forth in the application materials, sufficient for practical use of the invention.

The method of treatment is as follows.

For the implementation of the treatment in the patient originally imposed only drug on the basis of Aconite Jungar (extract). The patient begins taking the drug with a minimum dose (minimum dose, maximum dose, and the law of increasing its reception from minimum to maximum and Vice versa, the time of treatment depend on the type of disease, condition of the patient, extent of disease development). Each reception dose increase, until it reaches the maximum set value. Then in the body of the patient a certain time enters the maximum doses of the drug, and then each time the dose is gradually reduced to the minimum value. While taking maximum doses of the drug on the basis of Aconite Jungar, the patient is additionally administered activin protein family of TGF-β. The introduction of drugs into the patient carried out in a known manner.

For all examples have the same course of treatment: two months; the mode of administration of the drug on the basis of Aconite Jungar - receive ascending doses of 20 days, receiving the maximum dosage on the basis of Aconite Junggar together with activin - protein family of TGF-β 20 days, the drug-based Aconite Junggar with a gradual decrease in dose to 20 days. The drug (drugs) - daily.

Example 1. Sick So Diagnosis: breast cancer. Previously completed surgery for the removal of the breast. After the operation there was a relapse, which led to a sharp deterioration in health. Was determined by multiple lesions of the skull vault bones, spine, pelvis, chest, ribs, clavicles.

The patient was administered the extract of Aconite Junggar starting with a dose of 120 ng of total alkaloids in the first day of treatment and up to the maximum dose of 2.4 mcg per day 20. Together with the drug on the basis of Aconite Junggar from the calculation of the maximum dose within 20 days of taking the activin protein family of TGF-β, a single dose of 15 micrograms. After the end of the joint medications the patient has taken the drug on the basis of Aconite Jungar, gradually reducing the dose to 120 ng. Conducted four courses of treatment.

After the procedure a survey was conducted, which is th showed what happen active reparative processes in the lesions of the bones. Radiographic examination showed that the compaction of the bone structure; increase formations of bone tissue in all affected areas.

The patient recovered weight, increased vitality.

Example 2. Sick So Diagnosis: total gastric cancer with spread to the head of the pancreas. Was surgery. After the operation was gastrectomy with resection of the pancreatic head and duodenum. Diagnosis - nizkolegirovannaja adenocarcinoma with infiltrative growth and metastasis in the lymph node.

The patient took the drug on the basis of Aconite Jungar, starting with a dose of 120 ng on the first day of treatment and up to 2.4 mcg on the 20th, evenly increasing the dose. The patient then had a joint receiving maximum doses of the above-mentioned drug and activin - protein family of TGF-β, ravnomernij doses of 15 mcg, then followed the reception only of the drug on the basis of Aconite Jungar, with a gradual (evenly every day) dose reduction to 120 ng. Conducted four courses of treatment.

After treatment the patient feels well, went to work, put on weight, good appetite. After the treatment of recurrence was not detected.

Example molnau K. The diagnosis of Ewing sarcoma with metastases in the bone. Received combined chemotherapy. As a result of treatment was observed alopecia, decreased muscle tone, decreased vitality, apathy, depression. Conducted three courses of treatment in the manner described above. As a result of treatment restored the bone, the patient began to move independently, gained weight. Research has demonstrated full recovery from cancer.

A method of treating cancer, comprising introducing into the patient of the drug on the basis of Aconite in Dzhungarskiy daily increasing doses, characterized in that the quality of such product is used in the extract of Aconite Jungar, which is injected from the dose by total alkaloids 120 ng, evenly increasing the dose within 20 days to reach the value of 2.4 μg dose; during the next 20 days continue administration of the extract of Aconite Junggar at this dose, together with activin - protein family of TGF-β at the dose of 15 mcg; followed by the introduction of only one extract of Aconite Junggar with uniform daily dose reduction to 120 ng.



 

Same patents:

FIELD: organic chemistry, medicine, oncology.

SUBSTANCE: sensitizing agent for photodynamic disruption of malignant neoplasm cells represents a new compound - 18-hydroxy-substituted cycloimide of chlorine p6 or 7,8-dihydroxybacteriochlorine of the formula (I):

. Compounds of the formula (I) are used as an agent in treatment of malignant neoplasm. Invention expands assortment of sensitizing agents used in carrying out the photodynamic therapy.

EFFECT: valuable medicinal properties of agent.

6 cl, 1 dwg

FIELD: medicine, oncourology.

SUBSTANCE: the present innovation deals with conservative treatment of patients with malignant prostatic tumor at different stages. The method includes testicular enucleation, introduction of anti-tumor chemopreparations and radiation therapy. Moreover, in the onset of radiation therapy one should introduce 25 mg Cisplatin incubated with 10 ml patient's plasma into both prostatic lobes and paraprostatic fiber from the right and from the left. At achieving a focal dosage of 20 Gy one should repeat introduction of chemopreparation in similar dosage, and radiation therapy should be continued up to total focal dosage of 40 Gy. The innovation enables to decrease tumor sizes, side manifestations of radiation therapy at decreasing radiation loading and improve patient's life quality due to mitigating the urination.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with treating tumors of external reproductive organs in dogs: in preoperational period for 3 d one should introduce 20%-hypertonic solution of ACD-2 fraction upon 0.5%-novocaine solution at 0.1-0.3 ml working solution/cu. cm tumor into tumor basis, at not more than 0.4 ml pure ACD-2/10 kg canine body weight. One should dissect the tumor within the limits of healthy tissue, close vessels and wound defect after removing the tumor due to electrocoagulation of submucous layer at scab's development.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: oncological diseases.

SUBSTANCE: invention is designed for use in complex treatment of urinary bladder cancer in case of propagation of tumor to sub-epithelium connective tissue. Method comprises transurethral resection and introduction of immune preparations and furacillin solution. Once transurethral resection completed, three-way Foli catheter is transurethrally introduced to patient, through which mixture of standard furacillin solution with 10·106 ME interferon α-2β is injected from the first postoperative day and over following 3-5 postoperative days bringing summary dose of interferon to 50·106 ME.

EFFECT: prevented traumatism of urinary bladder due to single introduction of catheter and assured continuous action of drugs without development of immune complications.

FIELD: applied immunology.

SUBSTANCE: composition contains, wt parts: borax decahydrate1-25, sodium thiosulfate pentahydrate 10-5-10-4, potassium carbonate 30-150, refined sugar 30-200, and water 100-200 per 100 wt parts of sodium metasilicate pentahydrate. In addition to its capability of improving resistance to diseases, body weight increase, productivity of agricultural plants, quality of crop, and ripening term (harvest time), composition according to invention possesses nonspecific immunostimulating activity, including production of antibodies and enhancement of immunity through activation of immunocytes thereby maximally strengthening vaccination effect regarding diseases caused by malignant neoplasm viruses.

EFFECT: increased assortment of immunostimulating agents.

10 cl, 11 dwg, 12 ex

FIELD: medicine, oncology.

SUBSTANCE: method involves carrying out chemotherapy. Firstly, dose of nicotinic acid is administrated that is sufficient to initiate hyperemia of skin integuments and in appearance of first symptoms of hyperemia cytostatics are administrated by parenteral route. Method provides increasing duration of contact of cytostatics with tumor cells and micrometastasis due to inclusion of blood volumes depots in the parent state in vascular skin networks to volume of circulating blood. Invention can be used in treatment of malignant neoplasms with cutaneous and subcutaneous localization.

EFFECT: improved treatment method.

2 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to a photosensibilizing compound representing phenylthio-substituted derivative of phthalocyanine of the general formula (I): wherein R means hydrogen atom (H), t-C4H9; M means HH, AlOH, Zn. Also, invention relates to its liposomal formulation representing the composition of mixture of lipids (lecithin, cholesterol, cardiolipin) and a photosensibilizing agent, and to a method for carrying out the photodynamic therapy using this formulation. Photosensibilizing agents show high elimination rate from normal tissues, provide the deep therapeutic effect on tumor tissues, non-toxic properties and perspective for their using in oncology and other branches of medicine.

EFFECT: valuable medicinal properties of compound.

4 cl, 3 dwg, 9 ex

FIELD: medicine, oncology, pharmacy.

SUBSTANCE: invention relates to an anti-tumor agent representing benzoic acid amide (benzamide). Benzamide is used in the range of doses from 25 to 100 mg/kg.

EFFECT: expanded assortment of agents of indicated designation.

2 cl, 1 tbl

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to a new pentacyclic compound derivative of taxane represented by the formula:

wherein R1 represents dimethylaminomethyl group or morpholinomethyl group; R2 represents halogen atom or alkoxy-group comprising from 1 to 6 carbon atoms, or its salt eliciting an antitumor effect, and to a medicine agent based on its. Invention provides preparing new derivatives of taxane eliciting the valuable biological effect.

EFFECT: valuable medicinal properties of compound.

13 cl, 1 dwg, 4 tbl, 16 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of cyclic amide of the formula (I)

or its salt, or hydrate, or solvate wherein X represents (C1-C6)-alkyl, (C1-C6)-alkyl substituted with phenyl, (C2-C6)-alkenyl substituted with phenyl or halogenphenyl, (C2-C6)-alkynyl substituted with phenyl, phenyl that can be substituted with (C1-C6)-alkyl; one or more halogen atom, nitro-group, phenyl, (C1-C6)-alkoxy-group, halogen-(C1-C6)-alkyl, halogen-(C1-C6)-alkoxy-group, phenyl-(C1-C6)-alkyl, (C1-C6)-alkoxyphenyl-(C1-C6)-alkyl, amino-group, optionally substituted with (C1-C6)-alkyl, acetyl, (C1-C6)-alkoxy-group, substituted with phenyl, phenylcarbonyl, furanyl; 1- or 2-naphthyl, monocyclic (C3-C8)-cycloalkyl, amino-group substituted with one or more substitutes taken among phenyl, halogenphenyl, (C1-C6)-alkoxyphenyl, (C1-C6)-alkyl, halogen-(C1-C6)-alkyl, phenyl-(C1-C6)-alkyl; 5- or 6-membered monocyclic heterocyclic group comprising 1 or 2 heteroatoms, such as nitrogen (N), oxygen (O), sulfur (S) atom optionally substituted with halogenphenyl, halogen atom, benzyl, (C1-C6)-alkyl, phenyl; 8-10-membered bicyclic heteroaryl group comprising 1 or 2 heteroatoms taken among N, O and optionally substituted with halogen atom; 8-10-membered polycyclic cycloalkyl group; Q means -CH2-, -CO-, -O-, -S-, -CH(OR7)- or -C(=NR8)- wherein R7 means hydrogen atom (H), (C1-C6)-alkyl; R8 means OH, (C1-C)-alkoxy-group, acylamino-group, (C1-C6)-alkoxycarbonylamino-group, phenyl-(C1-C6)-alkoxy-group; n = 0-5; B represents group or wherein each among R3, R4, R5 and R6 represents independently substitute taken among group consisting of hydrogen atom (H), halogen atom, NO2 (nitro-group), (C1-C6)-alkoxy-group, CN (cyano-group); m = 1 or 2; ring represents 5- or 6-membered aromatic heterocyclic ring comprising one or two heteroatoms taken among O, S, N. Compound of the formula (I) elicit activity inhibiting binding sigma-receptors that allows their using as component of medicinal agent.

EFFECT: valuable medicinal properties of compounds.

21 cl, 2 sch, 4 tbl, 183 ex

FIELD: medicine, cardiology, gastroenterology.

SUBSTANCE: invention relates to a method for treatment of ulcer-erosion injures in gastroduodenal region in patients with arterial hypertension. Method involves detection of immune disturbances and carrying out the combined immunomodulating therapy and hypotensive therapy. Immunocorrecting complex consists of licopide, cortexinum, vetoronum TK in arterial hypertension of I-II degree and comprises superlymph additionally in arterial hypertension of III degree. Method provides attaining optimal results in treatment for relatively short time due to adequate immunocorrection in such patients.

EFFECT: improved method for treatment.

5 cl, 6 tbl, 2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to an agent with broad spectrum of biological effect. Agent based on natural interferon and/or recombinant interferon of α- and/or β- and/or γ-types. Agent is made in the form of different medicinal formulations and elicits immunomodulating, antibacterial, antioxidant and regenerating effect and designated for both internal using and external applying on skin and mucosa tissues. Invention provides the development of medicinal agent with broad spectrum of biological action. The prolonged administration of preparation doesn't effect on morphological composition of peripheral blood and has no effect on blood coagulation. The preparation doesn't show topical irritation and pyrogenic effect.

EFFECT: valuable medicinal properties of agent.

22 cl, 8 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to drugs for prevention and treatment of a variety of viral proliferative diseases and immunity disorders. Proposed solution contains: high-purity alpha-interferon; inert polymeric filler (in particular dextran or rheopolyglucin with molecular mass of dextran 30-50 kD); nonionic surfactant: tween 80, ethylenediaminetetraacetic acid or sodium salt thereof; buffer system including sodium acetate to provide solution pH 4.5-5.5; sodium chloride as osmotic pressure regulator; and injection water, all in specified proportions.

EFFECT: prolonged high activity and stability of preparation (up to 30 months) and improved quality characteristics thereof.

2 cl, 5 tbl, 2 ex

FIELD: medicine, radiation therapy.

SUBSTANCE: it is suggested to apply mixture prepared ex tempore out of: 5 mg hyoxison ointment, 1 ml 10% alpha-tocopherol acetate and 100 mcg superlymph-1 dissolved in 1 ml sterile distilled water. The suggested mixture should be applied twice daily onto affected part with thin layer to accelerate regeneration of affected tissue.

EFFECT: higher efficiency of therapy.

1 dwg

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with cryoprotective preparations that contain recombinant interferon-α2. The suggested cryoprotective preparation contains recombinant interferon-α2, polyethylene glycol 3000-6000, polyglucin, buffered 0.02%-Trilon B solution at pH being 5.5-7.0 and glycerol at certain ratio of components per 1.0 g preparation. The suggested cryoprotective preparation can additionally contain glycine, 3,7-bis(dimethylamino)phenothiazonium chloride, dry immunoglobulin preparation or dry immunoglobulin preparation for enteral intake. The present innovation provides maximal keeping the activity of recombinant interferon-α2 in cryoprotective preparation at multiple alteration of positive and negative environmental temperature and during storing this cryoprotective preparation under these conditions.

EFFECT: higher efficiency of application.

4 cl, 8 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with cryoprotective ointment containing recombinant interferon-α2. The suggested cryoprotective ointment contains recombinant interferon-α2, glycerol, polyethylene glycol 300-6000, polyglucin, buffered 0.02%-Trilon B solution at pH of 5.5-7.0 and ointment foundation at a certain content of components per 1.0 g ointment. Additionally, cryoprotective ointment could contain glycine 3,7-bis(dimethylamino)phenothiazonium chloride, dry immunoglobulin preparation or dry immunoglobulin preparation for enteral application. Ointment foundation of cryoprotective ointment could contain water-free lanolin, Vaseline and Vaseline oil, at the following ratio of components: 2.5;3.5:1 - 6.5:0.5:1. The innovation provides maximal safety of recombinant interferon-α2 activity in cryoprotective ointment at multiple alteration of positive and negative environmental temperature and at keeping cryoprotective ointment under these conditions.

EFFECT: higher efficiency of application.

8 cl, 8 ex

FIELD: medicine, dermatology.

SUBSTANCE: the suggested therapeutic method includes complex therapy with "Affinoleukin" being its one component. Depending upon the severity of disease flow, necessary dosages and the mode for preparation injection have been elaborated. The method provides efficient treatment due to competitive interaction of "Affinoleukin" with homologous antigens participating in pathogenesis of disease development that leads to interruption of disease symptoms being resistant to other kinds of therapy.

EFFECT: more prolonged period of remission.

4 cl, 3 ex, 2 tbl

FIELD: biology, medicine, pharmacology.

SUBSTANCE: invention relates to a method for elevating the amount of stem cells and/or hemopoietic precursor-cells in peripheral blood of mammals. Method involves administration of defibrotid in combination or in the direct temporal vicinity with at least one hemopoietic factor (preferably, with G-CSF) eliciting ability to activate hemopoietic precursor-cells. Invention provides elevating the amount of stem cells level.

EFFECT: improved elevating method, valuable medicinal properties of composition.

13 cl, 6 dwg, 6 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a composition eliciting an antibacterial effect. Composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides sufficient desorption of biologically active substances in resuspending the composition eliciting an antibacterial effect and comprising consortium of immunoglobulins.

EFFECT: valuable medicinal properties of composition.

5 ex

FIELD: medicine, pharmaceutical industry and technology, pharmacy.

SUBSTANCE: invention relates to a composition eliciting an antiviral effect. The composition comprises hydrophilic conglomerate of immunoglobulins consortium adsorbed with polyethylene glycol 4000-6000, recombinant interferon-α2 and a special additive taken among the following substances: glycine, glucose, maltose, sodium chloride taken in the definite ratio of components. Invention provides elevating solubility of composition eliciting an antiviral effect and enhanced release of biologically active substances to solution.

EFFECT: valuable medicinal properties of composition.

5 ex

FIELD: medicine, phytotherapy, pharmacy.

SUBSTANCE: invention relates to medicinal agents and can be used in preparing agent eliciting hepatoprotective activity. Method involves extraction of hexapetalous dropwort (Filipendula) roots and rhizomes with water at heating in the ratio raw : extractant = 1:(10-25) for 30 min, filtration, evaporation up to 1/3-1/5 of the parent volume and the following purification by cooling the evaporated concentrate, precipitation of the end product from its by addition of three-fold volume of 96% followed by settling, filtering off the precipitate and its successive washing out with 96% and ether. Invention provides enhancing the specific activity and pharmacological effect of agent.

EFFECT: improved preparing method.

1 tbl, 3 ex

Up!